Skip to main content
OpenTrials
Completed

NCT Number: NCT07450157

A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617

The aim of this study was to evaluate patient characteristics, treatment patterns, prostate-specific antigen (PSA) reduction, and overall survival (OS) of prostate cancer patients treated with 177-Lutetium-Prostate-Specific Membrane Antigen-617 (177Lu-PSMA-617). Patient data from multiple electronic health record databases, including claims (open-source medical and pharmacy claims), consumer attributes, mortality, and laboratory data linked to claims databases was used.

The study analysis was conducted in two phases. Phase I provided an early view of patients treated with 177Lu-PSMA-617 shortly after launch. Phase II refreshed the data, added mortality and extracted additional years of historical data to allow for the identification of the initial metastatic castrate-resistant prostate cancer (mCRPC) diagnosis and follow-up from that date through the start of 177Lu-PSMA-617.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Novartis

East Hanover, New Jersey, 07936, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Phase I inclusion criteria:

  • Patients with ≥1 claim in the open-source medical claims data with a Healthcare Common Procedure Coding System (HCPCS) code of A9607 or ≥1 claim in the open-source medical or pharmacy claims data with a National Drug Code (NDC) code for 177Lu-PSMA-617 during the patient selection window. The date of the first such claim is the index date.
  • For patients identified via NDC code, ≥1 claim with one of the following procedure codes on the same date as the 177Lu-PSMA-617 NDC claim: HCPCS - A9699, J3590; CPT 79191; or ≥1 claim with HCPCS code A9595 or A9597 occurring within 14 days before or after the index date.
  • At least 18 years of age at index date.
  • Patients with ≥2 medical claims ≥180 days prior to the index date.

For the treatment response analysis, the following additional criteria were applied:

  • Patients with linkage to lab data.
  • Patients with ≥1 PSA result available on or within 6 months prior to the index date. The PSA result closest to the index date was defined as the baseline PSA level.
  • Patients with ≥1 PSA result available after the index date.

Phase II inclusion criteria:

  • ≥2 medical claims (≥30 days apart) with a diagnosis of prostate cancer observed during the patient selection period.
  • ≥1 medical claim with a diagnosis code for metastatic disease occurring on or after the first observed prostate cancer diagnosis. The date of the first such claim was defined as the date of metastasis.
  • Evidence of castration resistance observed during the study period. The date of mCRPC diagnosis was defined as the latest of the date of metastasis and the date of castration resistance and must have occurred during the index window.
  • ≥12 months of continuous data availability prior to the mCRPC diagnosis date.
  • ≥1 claim for 177Lu-PSMA-617 after mCRPC diagnosis and continuous data availability between diagnosis and the date of 177Lu-PSMA-617 initiation.

Exclusion criteria

  • Standard data cleaning processes were applied to remove patients with data quality issues. Specific data quality issues included missing or invalid age or sex.

Treatment and study plan

Primary outcomes

  1. Number of Patients by Demographic Category

    Time frame: Baseline

    Demographics included:

    • Age group
    • Geographical region
    • Payer type
    • Physician specialty
    • Race/ethnicity
    • Education level
    • Occupation
  2. Number of Patients by Clinical Characteristic Category

    Time frame: Baseline

    Clinical characteristics included:

    • National Cancer Institute (NCI) comorbidity index
    • NCI category
    • Comorbidities
    • Metastasis sites
    • Number of distinct metastatic sites
    • PSA level category (≤ 4 ng/ml, > 4 ng/ml)
  3. Clinical Characteristic: Baseline PSA Level

    Time frame: Baseline

  4. Overall Survival (OS)

    Time frame: Up to approximately 10 years

    OS was defined as the time from mCRPC diagnosis until death.

  5. Number of Patients who Died Within 6, 12, 24, and 36 Months From the mCRPC Diagnosis Date

    Time frame: 6, 12, 24, and 36 months

  6. Survival Time After the Last Administration of 177Lu-PSMA-617

    Time frame: Up to approximately 10 years

  7. Number of Patients who Died After the Last Administration of 177Lu-PSMA-617

    Time frame: Up to approximately 10 years

Secondary outcomes

  1. Percentage of Patients by Treatments Received From mCRPC Diagnosis to Initiation of 177Lu-PSMA-617

    Time frame: Up to approximately 10 years

  2. Percentage of Patients by Line of 177Lu-PSMA-617 Initiation

    Time frame: Up to approximately 10 years

  3. Percentage of Patients by Sequence of Treatments Prior to 177Lu-PSMA-617 Treatment

    Time frame: Baseline

  4. Duration of Each Line of Treatment (LOT) by Treatment Received

    Time frame: Up to approximately 10 years

  5. Time From mCRPC Diagnosis to Initiation of 177Lu-PSMA-617

    Time frame: Up to approximately 10 years

  6. 177Lu-PSMA-617 Treatment Duration

    Time frame: Up to approximately 10 years

  7. Percentage of Patients Still on 177Lu-PSMA-617 Therapy at 3, 6, 9, and 12 Months After Initiation of 177Lu-PSMA-617

    Time frame: 3, 6, 9, and 12 Months

  8. Percentage of Patients by Number of 177Lu-PSMA-617 Cycles

    Time frame: Up to approximately 10 years

  9. Time to Next Treatment (TTNT)

    Time frame: Up to approximately 10 years

    TTNT was defined as time from the start of 177Lu-PSMA-617 therapy to the initiation of a new LOT.

  10. Number of Patients With a Change in PSA Levels While on 177Lu-PSMA-617 by Percent Reduction in PSA

    Time frame: Up to approximately 2 years

    Reduction in PSA was categorized as ≥50%, ≥80%, and ≥90%.

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

Patient Characteristics, Treatment Patterns and Outcomes Among Early Adopters of 177Lu-PSMA-617: An Early View Claims Data Study

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Mar 4, 2026
Registry last updated
Mar 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.